利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.018 秒)

    Tumor specific human monoclonal antibodies and methods of use
    2.
    发明申请
    Tumor specific human monoclonal antibodies and methods of use 审中-公开
    肿瘤特异性人单克隆抗体及使用方法

    公开(公告)号：US20050003469A1

    公开(公告)日：2005-01-06

    申请号：US10910124

    申请日：2004-08-02

    申请人： Jeffry Watkins ,  William Huse

    发明人： Jeffry Watkins ,  William Huse

    IPC分类号： A61K47/48 ,  C07K16/30 ,  G01N33/574 ,  C07K16/28

    CPC分类号： C07K16/3069 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/3023 ,  C07K2317/21 ,  C07K2317/565

    摘要： The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.

    摘要翻译： 本发明提供肿瘤特异性人单克隆抗体和功能片段。 还提供了编码肿瘤特异性人单克隆抗体和功能片段的核酸。 还提供了减少肿瘤细胞增殖的方法。 该方法包括施用有效量的肿瘤特异性人单克隆抗体或功能片段。 还提供了检测样品中的肿瘤细胞的方法。 该方法包括使细胞与肿瘤特异性单克隆抗体或功能片段接触并检测人单克隆抗体或功能片段与样品的特异性结合。

    Recombinant IL-9 antibodies and uses thereof
    3.
    发明授权
    Recombinant IL-9 antibodies and uses thereof 失效
    重组IL-9抗体及其用途

    公开(公告)号：US08481037B2

    公开(公告)日：2013-07-09

    申请号：US13007211

    申请日：2011-01-14

    申请人： Jennifer Lynne Reed ,  Herren Wu ,  Ying Tang ,  Julian Davies ,  Jeffry Watkins

    发明人： Jennifer Lynne Reed ,  Herren Wu ,  Ying Tang ,  Julian Davies ,  Jeffry Watkins

    IPC分类号： A61K39/395

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    摘要： The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

    摘要翻译： 本发明提供免疫特异性结合IL-9多肽的新型抗体和包含所述抗体的组合物。 本发明还提供了预防，治疗，治疗和/或改善与IL 9或IL-9受体或其亚基的异常表达和/或活性相关的疾病和病症的方法和组合物，自身免疫性疾病，炎性疾病，增殖性疾病， 以及感染，其包括施用一种或多种免疫特异性结合IL-9多肽的抗体。 本发明还包括用于诊断，监测和预测这些疾病的方法和组合物。 本发明还涉及包含免疫特异性结合IL-9多肽的抗体的制品和试剂盒。

    Human il-1 beta antagonists
    5.
    发明申请
    Human il-1 beta antagonists 有权
    人类il-1β拮抗剂

    公开(公告)号：US20060140932A1

    公开(公告)日：2006-06-29

    申请号：US10542508

    申请日：2004-01-21

    申请人： Craig Dickinson ,  Alain Vasserot ,  Jeffry Watkins ,  Jirong Lu

    发明人： Craig Dickinson ,  Alain Vasserot ,  Jeffry Watkins ,  Jirong Lu

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/245 ,  A61K2039/505 ,  C07K2317/565

    摘要： The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.

    摘要翻译： 本发明包括与成熟的人IL-1β特异性结合的分离的抗体或其抗原结合部分。 这些抗体或其抗原结合部分通常表现出高的结合亲和力（低k值），与天然抗体相比减少了脱酰胺化，并且可用于治疗各种疾病如类风湿性关节炎 ，骨关节炎或神经炎症。

    Humanized collagen antibodies and related methods
    6.
    发明申请
    Humanized collagen antibodies and related methods 失效
    人源化胶原抗体及相关方法

    公开(公告)号：US20070077199A1

    公开(公告)日：2007-04-05

    申请号：US11486894

    申请日：2006-07-14

    申请人： Jeffry Watkins ,  William Huse ,  Ying Tang ,  Daniel Broek ,  Peter Brooks

    发明人： Jeffry Watkins ,  William Huse ,  Ying Tang ,  Daniel Broek ,  Peter Brooks

    IPC分类号： A61K51/00 ,  G01N33/574 ,  A61K39/395 ,  C07K16/30 ,  C07K16/46

    CPC分类号： C07K16/30 ,  A61K47/6843 ,  A61K47/6851 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565

    摘要： The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

    摘要翻译： 本发明提供抗体或其功能片段，其接枝抗体或其功能片段，其包含一个或多个在重链CDR的一个或多个CDR中具有至少一个氨基酸取代的互补决定区（CDR），其中 抗体或其功能片段对隐窝胶原表位具有特异性结合活性。 本发明还提供了使用具有对神经胶原表位具有特异性结合活性的抗体的方法，包括抑制血管发生，肿瘤生长和转移的方法。

    Tumor specific monoclonal antibodies
    7.
    发明申请
    Tumor specific monoclonal antibodies 审中-公开

    公开(公告)号：US20060228366A1

    公开(公告)日：2006-10-12

    申请号：US11413563

    申请日：2006-04-28

    申请人： Jeffry Watkins

    发明人： Jeffry Watkins

    IPC分类号： A61K39/395 ,  C07K16/46 ,  C07K16/30

    CPC分类号： C07K16/00 ,  A61K2039/505 ,  A61K2039/5152 ,  C07K16/3015 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/77

    摘要： The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.

    ß binding molecules
    8.
    发明申请
    ß binding molecules 有权
    β结合分子

    公开(公告)号：US20060110388A1

    公开(公告)日：2006-05-25

    申请号：US10544050

    申请日：2004-02-06

    申请人： Julian Davies ,  Ying Tang ,  Jeffry Watkins

    发明人： Julian Davies ,  Ying Tang ,  Jeffry Watkins

    IPC分类号： A61K39/395 ,  C07K16/18

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

    摘要： The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译： 本发明包括使用衍生自鼠抗体266的互补决定区的鼠抗体266的人源化变体的分离的抗体或其片段。变体抗体可用于治疗或预防与Aβ相关的病症和疾病，包括阿尔茨海默氏病 唐氏综合征，脑淀粉样血管病，轻度认知障碍等。

    Heteromeric variable regions with unvaried human framework regions
    9.
    发明申请
    Heteromeric variable regions with unvaried human framework regions 审中-公开

    公开(公告)号：US20050064438A1

    公开(公告)日：2005-03-24

    申请号：US10697400

    申请日：2003-10-30

    申请人： William Huse ,  Jeffry Watkins ,  Herren Wu

    发明人： William Huse ,  Jeffry Watkins ,  Herren Wu

    IPC分类号： C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  C12Q1/68 ,  G01N33/48 ,  G01N33/50 ,  G06F19/00

    CPC分类号： C07K16/465 ,  C07K16/00 ,  C07K16/2878 ,  C07K16/36 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

    摘要： The invention provides a method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework. The method consists of: (a) constructing a population of altered antibody variable region encoding nucleic acids, said population comprising encoding nucleic acids for an acceptor variable region framework containing a plurality of different amino acids at one or more acceptor framework region amino acid positions and donor CDRs containing a plurality of different amino acids at one or more donor CDR amino acid positions; (b) expressing said population of altered variable region encoding nucleic acids, and (c) identifying one or more altered variable regions having binding affinity substantially the same or greater than the donor CDR variable region. The acceptor variable region framework can be a heavy or light chain variable region framework and the populations of heavy and light chain altered variable regions can be expressed alone to identify heavy or light chains having binding affinity substantially the same or greater than the donor CDR variable region. The populations of heavy and light chains additionally can be coexpressed to identify heteromeric altered variable region binding fragments. The invention also provides a method of simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. The method consists of: (a) constructing a population of altered heavy chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework region and CDR amino acid positions; (b) constructing a population of altered light chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework regions and CDR amino acid positions; (c) coexpressing said populations of heavy and light chain variable region encoding nucleic acids to produce diverse combinations of heteromeric variable region binding fragments, and (d) identifying one or more heteromeric variable region binding fragments having affinity substantially the same or greater than the donor CDR heteromeric variable region binding fragment. A method of optimizing the binding affinity of an antibody variable region is also provided. The method consists of: (a) constructing a population of antibody variable region encoding nucleic acids, said population comprising two or more CDRs containing a plurality of different amino acids at one or more CDR amino acid positions; (b) expressing said population of variable region encoding nucleic acids, and (c) identifying one or more variable regions having binding affinity substantially the same or greater than the donor CDR variable region. The variable region populations can be heavy or light chains and can be expressed as individual populations or they can be coexpressed to produce heteromeric variable region binding fragments.